Merck & Co., Inc. (MRK) intrinsic value & 10-year financials

Merck & Co., Inc. (MRK) has a Graham intrinsic value of $241.81 per share. At $143.63 on Oct 20, 2026, the stock trades 41% below that value. Over the last 10 fiscal years revenue grew 5.6% a year to $65.0B, with an average return on invested capital of 15.8%.

Graham intrinsic value
$241.81
Share price (Oct 20, 2026)
$143.63
Price vs Graham value
41% below
Market cap
$360.1B
Revenue (FY2025)
$65.0B
Revenue growth (10-yr CAGR)
5.6%
ROIC (10-yr avg)
15.8%
Free cash flow (FY2025)
$12.4B

MRK 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $65.0B $18.3B $7.28 $12.4B — 23.0%
FY2024 $64.2B $17.1B $6.74 $18.1B — 24.9%
FY2023 $60.1B $365.0M $0.14 $9.1B — 0.6%
FY2022 $59.3B $14.5B $5.71 $14.7B — 22.5%
FY2021 $48.7B $13.0B $5.14 $8.7B — 23.6%
FY2020 $48.0B $7.1B $2.78 $5.6B — 16.1%
FY2019 $46.8B $9.8B $3.81 $10.0B — 23.0%
FY2018 $42.3B $6.2B $2.32 $8.3B — 12.9%
FY2017 $40.1B $2.4B $0.87 $4.6B — 4.3%
FY2016 $39.8B $3.9B $1.41 $8.8B — 6.7%

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

Merck & Co. has demonstrated mature, steady growth, with revenue compounding at 5.6% annually over the past decade.

Merck & Co. has earned high returns on invested capital, averaging 15.8% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.

Over the decade, Merck & Co. shows that the company has leveraged its balance sheet to sustain operations.

Benjamin Graham lens

Under Benjamin Graham's formula using SEC EDGAR fundamentals, Merck & Co. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $241.81 per share.

MRK stock: frequently asked questions

What is the intrinsic value of Merck & Co., Inc. (MRK) stock?

Using Benjamin Graham's revised formula, V = EPS × (8.5 + 2g) × 4.4 / Y, with reported diluted earnings per share, a 15.0% normalized growth rate (capped at 15%) and a 5.1% AAA corporate bond yield, MRK's intrinsic value is about $241.81 per share.

Is MRK stock undervalued?

At $143.63 (close on Oct 20, 2026), MRK trades 41% below its Graham value of $241.81. On Graham's terms that leaves a margin of safety. A formula is a starting point for research, not a recommendation.

How fast has Merck & Co., Inc. grown?

Revenue went from $39.8B in fiscal 2016 to $65.0B in fiscal 2025, a compound annual growth rate of 5.6%. Net income was $18.3B in fiscal 2025.

Does Merck & Co., Inc. generate free cash flow?

Merck & Co., Inc. generated $12.4B of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 10 of the last 10 reported years.

What is MRK's return on invested capital?

Average ROIC over the last 10 fiscal years was 15.8%, and average return on equity was 25.6%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this MRK data come from?

From Merck & Co., Inc.'s annual 10-K filings on SEC EDGAR. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks